2-propanol has been researched along with Ache in 13 studies
2-Propanol: An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.
propan-2-ol : A secondary alcohol that is propane in which one of the hydrogens attached to the central carbon is substituted by a hydroxy group.
Excerpt | Relevance | Reference |
---|---|---|
"Long-term postoperative complications were observed between 6 months and 5 years of follow-up." | 1.27 | Complications associated with the use of silicone oil in 150 eyes after retina-vitreous surgery. ( Federman, JL; Schubert, HD, 1988) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (46.15) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (15.38) | 29.6817 |
2010's | 2 (15.38) | 24.3611 |
2020's | 3 (23.08) | 2.80 |
Authors | Studies |
---|---|
Ramsook, C | 1 |
Kozinetz, CA | 1 |
Moro-Sutherland, D | 1 |
Chambers, S | 1 |
Leftwich, T | 1 |
Pamonag, M | 1 |
Rice, J | 1 |
Walker, MT | 1 |
Hallali, G | 3 |
Aubert, T | 3 |
Souied, EH | 3 |
Glacet-Bernard, A | 3 |
Cui, L | 1 |
Ma, Y | 1 |
Wang, Y | 1 |
Luo, Q | 1 |
Ding, Q | 1 |
Ge, L | 1 |
Lu, S | 1 |
Miao, Y | 1 |
Sun, Q | 1 |
Zou, H | 1 |
Jin, H | 1 |
Lee, CS | 1 |
Kim, DK | 1 |
Lee, SC | 1 |
Kotecha, A | 1 |
Spratt, A | 1 |
Ogunbowale, L | 1 |
dell'Omo, R | 1 |
Kulkarni, A | 1 |
Bunce, C | 1 |
Franks, WA | 1 |
SUTTON, PR | 1 |
TAIT, EC | 1 |
TORNETTA, FJ | 1 |
O'Brien, PD | 1 |
Fitzpatrick, P | 1 |
Power, W | 1 |
Schon, F | 1 |
Federman, JL | 1 |
Schubert, HD | 1 |
Lowe, RF | 1 |
Zuazo, A | 1 |
IbaƱez, J | 1 |
Belmonte, C | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Efficacy of the Eutectic Mixture of Local Anesthetics (EMLA) Cream Versus the Synera Patch for Pain Reduction During Venipuncture in Children[NCT00530803] | Phase 2 | 100 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The NRS (Numerical Rating Scale) is a 6-point rating scale where 0= no pain and 5 = worst pain. Blinded observers reported their own subjective evaluation of the level of pain experienced by the participants at tourniquet placement. Total number of participants subjectively evaluated as experiencing each pain level is reported. (NCT00530803)
Timeframe: before venipuncture
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Participants evaluated at NRS = 0 (No pain) | Participants evaluated at NRS = 1 | Participants evaluated at NRS = 2 | Participants evaluated at NRS = 3 | Participants evaluated at NRS = 4 | Participants evaluated at NRS = 5 | |
EMLA Cream | 41 | 6 | 2 | 1 | 0 | 0 |
Synera Patch | 37 | 6 | 5 | 1 | 1 | 0 |
The NRS (Numerical Rating Scale) is a 6-point rating scale where 0= no pain and 5 = worst pain. Blinded observers reported their own subjective evaluation of the level of pain participants were experiencing 5 minutes after the venipuncture was completed. Total number of participants subjectively evaluated as experiencing each pain level is reported. (NCT00530803)
Timeframe: 5 minutes post venipuncture
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Participants evaluated at NRS = 0 (No pain) | Participants evaluated at NRS = 1 | Participants evaluated at NRS = 2 | Participants evaluated at NRS = 3 | Participants evaluated at NRS = 4 | Participants evaluated at NRS = 5 | |
EMLA Cream | 45 | 3 | 1 | 1 | 0 | 0 |
Synera Patch | 45 | 4 | 1 | 0 | 0 | 0 |
The NRS (Numerical Rating Scale) is a 6-point rating scale where 0= no pain and 5 = worst pain. Blinded observers reported their own subjective evaluation of the level of pain experienced by the participants at needle insertion. Total number of participants subjectively evaluated as experiencing each pain level is reported. (NCT00530803)
Timeframe: during needle insertion
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Participants evaluated at NRS = 0 (No pain) | Participants evaluated at NRS = 1 | Participants evaluated at NRS = 2 | Participants evaluated at NRS = 3 | Participants evaluated at NRS = 4 | Participants evaluated at NRS = 5 | |
EMLA Cream | 32 | 14 | 2 | 2 | 0 | 0 |
Synera Patch | 25 | 12 | 9 | 2 | 2 | 0 |
The Numerical Rating Scale (NRS) is a 6-point rating scale where 0= no pain and 5 = worst pain. Parents reported their own subjective evaluation of participants pain level. Each participant had only one parental assessment. Total number of parental assessment for each pain level on the 6-point NRS is reported as total number of participants experiencing that pain level. (NCT00530803)
Timeframe: immediately after venipuncture is completed
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
number of participants with NRS=0 (no pain) | number of participants with NRS=1 | number of participants with NRS=2 | number of participants with NRS=3 | number of participants with NRS=4 | number of participants with NRS=5 | |
EMLA Cream | 42 | 6 | 1 | 1 | 0 | 0 |
Synera Patch | 41 | 5 | 1 | 2 | 0 | 1 |
"Participants were asked to report their level of pain using a 6-point Wong-Baker FACES Pain Rating Scale ranging from 0, no pain, to 5, the most pain you can have. The Wong-Baker FACES Pain Rating Scale is a validated tool for measuring pain in patients as young as 3 years old. A FACES pain score less than or equal to 2 is considered no pain to mild pain, and is clinically acceptable. Studies have shown average FACES pain scores for children receiving vascular access with placebo to be 2.2 to 3.5." (NCT00530803)
Timeframe: immediately after completion of venipuncture
Intervention | Participants (Count of Participants) | |||||
---|---|---|---|---|---|---|
Participants with FACES Score = 0 (No pain) | Participants with FACES Score = 1 | Participants with FACES Score = 2 | Participants with FACES Score = 3 | Participants with FACES Score = 4 | Participants with FACES Score = 5 | |
EMLA Cream | 42 | 6 | 2 | 0 | 0 | 0 |
Synera Patch | 38 | 8 | 3 | 1 | 0 | 0 |
1 review available for 2-propanol and Ache
Article | Year |
---|---|
Postsympathectomy pain and changes in sensory neuropeptides: towards an animal model.
Topics: Animals; Calcitonin Gene-Related Peptide; Iris; Lumbosacral Region; Nerve Fibers; Nerve Growth Facto | 1985 |
1 trial available for 2-propanol and Ache
Article | Year |
---|---|
Efficacy of ethyl chloride as a local anesthetic for venipuncture and intravenous cannula insertion in a pediatric emergency department.
Topics: 2-Propanol; Administration, Cutaneous; Adolescent; Aerosols; Anesthetics, Local; Child; Child, Presc | 2001 |
11 other studies available for 2-propanol and Ache
Article | Year |
---|---|
Trpm1: Novel function at the intersection of light and pain response in the iris.
Topics: Animals; Color Vision; Iris; Mammals; Mice; Mice, Knockout; Pain; Reflex, Pupillary; Retina; Rod Ops | 2022 |
Lens-Iris diaphragm retropulsion syndrome: Risk factors and management. A prospective study.
Topics: Cataract Extraction; Humans; Intraoperative Complications; Iris; Pain; Phacoemulsification; Postoper | 2023 |
Lens-Iris diaphragm retropulsion syndrome: Risk factors and management. A prospective study.
Topics: Cataract Extraction; Humans; Intraoperative Complications; Iris; Pain; Phacoemulsification; Postoper | 2023 |
Lens-Iris diaphragm retropulsion syndrome: Risk factors and management. A prospective study.
Topics: Cataract Extraction; Humans; Intraoperative Complications; Iris; Pain; Phacoemulsification; Postoper | 2023 |
Lens-Iris diaphragm retropulsion syndrome: Risk factors and management. A prospective study.
Topics: Cataract Extraction; Humans; Intraoperative Complications; Iris; Pain; Phacoemulsification; Postoper | 2023 |
Combination of iris vessel area density and surgery interval as the predictor of perceived pain during consecutive second-eye cataract surgery.
Topics: Case-Control Studies; Cataract; Cataract Extraction; China; Humans; Iris; Pain; Pain Perception; Pha | 2023 |
A case of ciliary body melanocytoma presenting as a painful iris mass.
Topics: Ciliary Body; Humans; Iris; Male; Middle Aged; Neoplasm Invasiveness; Nevus; Pain; Uveal Neoplasms | 2010 |
Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Association between colour of the iris of the eye and reaction to dental pain.
Topics: Color; Dental Caries; Humans; Iris; Pain; Toothache | 1959 |
NEUROLEPT-ANALGESIA AS ADJUNCT TO LOCAL ANESTHESIA IN INTRAOCULAR SURGERY; A PRELIMINARY REPORT.
Topics: Adjuvants, Anesthesia; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anesthesia, Local; Antipyret | 1965 |
Patient pain during stretching of small pupils in phacoemulsification performed using topical anesthesia.
Topics: Aged; Aged, 80 and over; Anesthesia, Local; Anesthetics, Local; Female; Humans; Iris; Male; Pain; Pa | 2005 |
Complications associated with the use of silicone oil in 150 eyes after retina-vitreous surgery.
Topics: Cataract; Chronic Disease; Corneal Diseases; Emulsions; Eye Diseases; Glaucoma; Humans; Iris; Pain; | 1988 |
Persistent symptoms after peripheral iridectomy for angle-closure glaucoma.
Topics: Acute Disease; Adult; Aged; Female; Glaucoma; Humans; Intraocular Pressure; Iris; Middle Aged; Pain; | 1987 |
Sensory nerve responses elicited by experimental ocular hypertension.
Topics: Action Potentials; Animals; Cats; Cornea; Eye; Glaucoma; Intraocular Pressure; Iris; Neurons, Affere | 1986 |